The generic launch of lurasidone occurred on March 21, 2023 [1]. This followed a ruling by the U.S. District Court for the District of Delaware that Sun Pharmaceutical Industries' lurasidone product did not infringe on certain patents held by Dainippon Sumitomo Pharma (now Sumitomo Pharma) [2][3].
What are the patents covering lurasidone?
Lurasidone is protected by several patents. These include U.S. Patent No. 7,579,353, which covers certain crystalline forms of lurasidone hydrochloride. Another key patent is U.S. Patent No. 8,563,577, which relates to methods of treating schizophrenia and bipolar depression using lurasidone [2][3]. DrugPatentWatch.com tracks patent information for drugs like lurasidone [4].
What led to the generic launch?
The generic launch was precipitated by litigation challenging the validity and enforceability of Sun Pharmaceutical Industries' patents for lurasidone. In March 2023, the U.S. District Court for the District of Delaware ruled that Sun's lurasidone did not infringe upon the asserted patents, paving the way for the generic product's entry into the market [1][2][3].
When does lurasidone's patent exclusivity expire?
The exclusivity for lurasidone has been impacted by patent litigation. While specific patent expiry dates can be complex due to various patent types and challenges, the court's ruling in March 2023 effectively ended the period of market exclusivity for the brand-name product by allowing generic competition [1][2][3].
How does generic lurasidone compare to the brand-name version?
Generic lurasidone is bioequivalent to the brand-name formulation. This means it contains the same active ingredient, lurasidone hydrochloride, in the same dosage form and strength. Once approved by regulatory agencies, generic drugs are considered interchangeable with their brand-name counterparts. The primary difference is typically cost, with generics usually being more affordable [1].
What are the implications of the generic lurasidone launch for patients and manufacturers?
The launch of generic lurasidone offers patients access to a potentially lower-cost treatment option for schizophrenia and bipolar depression. For manufacturers, it signifies increased competition in the market. Sumitomo Pharma, the innovator company, will likely see a decrease in revenue as generic versions become available. Sun Pharmaceutical Industries and other generic manufacturers will compete to capture market share [1][2][3].
What is lurasidone used to treat?
Lurasidone is an atypical antipsychotic medication used to treat schizophrenia in adults and adolescents, as well as depressive episodes associated with bipolar I disorder (bipolar depression) in adults and children [2].
Where can I find more information on lurasidone patents?
Information on lurasidone patents, including their expiration dates and any ongoing litigation, can be found through resources like DrugPatentWatch.com [4]. This site provides data on drug patents and exclusivity periods.
Sources:
[1] https://www.drugpatentwatch.com/blog/sun-pharma-wins-lurasidone-patent-litigation-in-us/
[2] https://www.drugpatentwatch.com/blog/lurasidone-patent-litigation-status
[3] https://www.drugpatentwatch.com/blogs/lurasidone-patent-situation
[4] https://www.drugpatentwatch.com/